Ocean Biomedical: Dr. Jonathan Kurtis, MD issued patent for malaria treatment

Ocean Biomedical announced that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfGARP…This patent is adding to Ocean Biomedical’s global patent portfolio of over 5 dozen patents for discoveries with potential to impact major unmet medical needs in infectious disease, oncology, and fibrosis, developed through grants totaling over $125M. Kurtis’ novel approach causes parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This patent expands protection for Dr. Kurtis’ novel discoveries at …a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs”The resurgence of Falciparum malaria worldwide is increasingly alarming and we are pleased to see Dr. Kurtis’ work receive this patent coverage for such an important discovery. We will work hard to accelerate the development of our novel vaccine candidate and this novel class of antimalarial antibodies to get a new treatment option for severe malaria available as soon as possible,” said Dr. Chirinjeev Kathuria, co-founder and Executive Chairman.